Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.

Chronic myelogenous leukemia (CML) is characterized by a reciprocal chromosomal translocation (9;22) that generates the Bcr-Abl fusion gene. BCR-ABL transforming activity is mediated by critical downstream signaling pathways that are aberrantly activated by tyrosine kinases. However, the mechanisms of BCR-ABL anti-apoptotic effects and the signaling pathways by which BCR-ABL influences apoptosis in BCR-ABL-expressing cells are poorly defined. In this study, we found that treatment with ABL kinase inhibitors or depletion of BCR-ABL induced the expression of RAB45 messenger RNA and protein and induced apoptosis via reduction of mitochondrial membrane potential and p38 activation in CML cell lines and BCR-ABL(+) progenitor cells from CML patients. Overexpressed RAB45 induced the activation of caspases-3 and -9 and reduced the expression of Survivin, XIAP, c-IAP1 and c-IAP2 in CML cells. Moreover, in colony-forming cells derived from CML-aldehyde dehydrogenase(hi)/CD34(+) cells, treatment with ABL kinase inhibitors induced RAB45 expression and reduced mitochondrial membrane potential, resulting in inhibited colony formation of Bcr-Abl(+) progenitor cells. The overexpression of RAB45 significantly decreased colony numbers and induced apoptosis through the activation of caspases-3 and -9. Furthermore, the overexpression of RAB45 increased the phosphorylation levels of p38, resulting in the induction of apoptosis and inhibition of proliferation of CML progenitor cells. Our results identify a new signaling molecule involved in BCR-ABL modulation of apoptosis and suggest that RAB45 induction strategies may have therapeutic utility in patients with CML.

[1]  Bor Luen Tang,et al.  Emerging roles for Rab family GTPases in human cancer. , 2009, Biochimica et biophysica acta.

[2]  Shawn M. Sweeney,et al.  Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. , 2000, Blood.

[3]  A. Ganser,et al.  Specific inhibition of bcr-abl gene expression by small interfering RNA. , 2003, Blood.

[4]  P. Novick,et al.  Role of Rab GTPases in membrane traffic and cell physiology. , 2011, Physiological reviews.

[5]  Gordon B. Mills,et al.  Derailed endocytosis: an emerging feature of cancer , 2008, Nature Reviews Cancer.

[6]  D. Kobayashi,et al.  Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. , 2001, Anticancer research.

[7]  D. Green,et al.  Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. , 1998, Blood.

[8]  J. Goldenring,et al.  Rab25 as a tumour suppressor in colon carcinogenesis , 2010, British Journal of Cancer.

[9]  S. Park,et al.  The role of p38 MAPK activation in auranofin‐induced apoptosis of human promyelocytic leukaemia HL‐60 cells , 2005, British journal of pharmacology.

[10]  Zheng Zhao,et al.  Delineation of the minimal commonly deleted segment and identification of candidate tumor‐suppressor genes in del(9q) acute myeloid leukemia , 2005, Genes, chromosomes & cancer.

[11]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[12]  Yun Dai,et al.  A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2* , 2004, Journal of Biological Chemistry.

[13]  D. Green,et al.  Bcl-2-independent Bcr–Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL , 1998, Oncogene.

[14]  E. Andreu,et al.  Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL , 2000, The Journal of experimental medicine.

[15]  E. Canaani,et al.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.

[16]  Satoki Nakamura,et al.  KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells. , 2008, Leukemia research.

[17]  B. Calabretta,et al.  Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. , 2000, Blood.

[18]  S. Derdak,et al.  Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. , 2005, Blood.

[19]  T. Inaba,et al.  Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors , 2004, Molecular and Cellular Biology.

[20]  A. Verma,et al.  Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells* , 2004, Journal of Biological Chemistry.

[21]  A. Verma,et al.  Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib , 2009, Leukemia & lymphoma.

[22]  T. Ueda,et al.  Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. , 2003, Anticancer Research.

[23]  J U Gutterman,et al.  The molecular genetics of Philadelphia chromosome-positive leukemias. , 1988, The New England journal of medicine.

[24]  L Bibbs,et al.  A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. , 1994, Science.

[25]  N. Gruis,et al.  Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma. , 2008, Investigative ophthalmology & visual science.

[26]  P. Nowell,et al.  DNA Contents of Chromosome Ph1 and Chromosome 21 in Human Chronic Granulocytic Leukemia , 1964, Science.

[27]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[28]  C. Sawyers,et al.  Signal transduction by wild-type and leukemogenic Abl proteins. , 1997, Biochimica et biophysica acta.

[29]  J. Pereira-Leal,et al.  Evolution of the Rab family of small GTP-binding proteins. , 2001, Journal of molecular biology.

[30]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[31]  D. Cortez,et al.  Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis , 1995, Molecular and cellular biology.

[32]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[33]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[34]  B. Druker,et al.  Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. , 2005, Cancer research.

[35]  O. Witte,et al.  Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. , 2003, Blood.

[36]  M. Hengartner The biochemistry of apoptosis , 2000, Nature.

[37]  Osamu Miura,et al.  Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. , 2009, Cancer research.

[38]  H. J. Kim,et al.  An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. , 2001, Biochemistry.

[39]  J. Sampath,et al.  Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. , 2005, Cancer research.

[40]  E. Lam,et al.  Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells , 2005, Oncogene.

[41]  I. Weissman,et al.  Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  H. Kajiho,et al.  Characterization of Rab45/RASEF containing EF-hand domain and a coiled-coil motif as a self-associating GTPase. , 2007, Biochemical and biophysical research communications.

[43]  John Calvin Reed,et al.  Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. , 2000, Neoplasia.

[44]  Jukka Westermarck,et al.  Phosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  S. Pfeffer A model for Rab GTPase localization. , 2005, Biochemical Society transactions.

[46]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[47]  I. McNeish,et al.  Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy , 2003, Oncogene.

[48]  F. Durrieu,et al.  Bcr-abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines , 1997, Cell Death and Differentiation.

[49]  J. Goldenring,et al.  Regulation of Vesicle Trafficking in Madin-Darby Canine Kidney Cells by Rab11a and Rab25* , 2000, The Journal of Biological Chemistry.

[50]  Satoki Nakamura,et al.  The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. , 2010, Carcinogenesis.

[51]  G. Mills,et al.  The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers , 2004, Nature Medicine.

[52]  G. Pagès,et al.  Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function , 2003, Oncogene.

[53]  W. El-Deiry,et al.  BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. , 1995, Blood.